Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652130 · ClinicalTrials.gov registry record · Phase 3
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
A Phase 3 study of Grade B Acute Graft Versus Host Disease and Grade C Acute Graft Versus Host Disease, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 20
- Study locations
NCT02652130: Completed Phase 3 study of Grade B Acute Graft Versus Host Disease and Grade C Acute Graft Versus Host Disease, sponsored by Mesoblast.
NCT02652130 is a Phase 3 study of Grade B Acute Graft Versus Host Disease and Grade C Acute Graft Versus Host Disease that has completed, run by Mesoblast. The registered enrollment target is 32 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02652130, a Phase 3 study of Grade B Acute Graft Versus Host Disease and Grade C Acute Graft Versus Host Disease, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 20
- Study locations
Study Summary
Ongoing safety assessment follow-up to Protocol MSB-GVHD001 (NCT02336230) of remestemcel-L treatment in pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT), that have failed to respond to treatment with systemic corticosteroid therapy.
Primary Outcome
The overall survival rate is defined as the percentage of participants alive at the given time point. OS is defined as the time to death from the start of drug therapy.
Conditions Studied
Interventions
- BIOLOGICAL Remestemcel-L
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- CHOC Children's Hospital of Orange County - Orange
- UCSF Benioff Children's Hospital - San Francisco
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- The Children's Hospital at Montefiore - New York
Colorado
- Children's Hospital Colorado Center for Cancer/Blood Disorders - Aurora
Delaware
- Alfred I. duPont Hospital for Children of the Nemours Foundation - Wilmington
Florida
- Miami Children's Research Institute - Miami
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Michigan
- Children's Hospital of Michigan - Detroit
Mississippi
- University of Mississippi Medical Center - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2018-06-15 |
| Phase | Phase 3 |
What the finished NCT02652130 record still lists
NCT02652130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Grade B Acute Graft Versus Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Remestemcel-L is the first listed.
NCT02652130 names 20 study sites across 16 states, led by California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT02652130 about?
NCT02652130 is a clinical study titled "Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD". Ongoing safety assessment follow-up to Protocol MSB-GVHD001 (NCT02336230) of remestemcel-L treatment in pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT), that have failed to respond to treatment with systemic corticos...
What is the current status of trial NCT02652130?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2015-10-28. Estimated completion is 2018-06-15.
What conditions does trial NCT02652130 study?
This clinical trial studies the following conditions: Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease.
What interventions are being tested in trial NCT02652130?
The interventions under investigation include: Remestemcel-L (BIOLOGICAL).
Who is sponsoring clinical trial NCT02652130?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02652130 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02652130's enrollment target sits among peer trials
32 1909th of 2000 higher than 87 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI